Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Analyst
Andy Ranieri
Period: Reporting period mapped to calendar 2026 Q1.
- Questions
- 2on tracked calls
- Challenge rate
- 0%none of 2 questionsLimited sample
- Companies
- 1questioned at least once
- Reporting periods
- 1with questions
These figures cover the whole profile: every tracked question, all reporting periods.
How to read these numbers
Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.
Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.
No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.
Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.
Small samples. Profiles with fewer than 10 questions are marked Limited sample.
Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.
Questions asked
Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.
Showing 2 of 2 questions from 1 company
SYKStryker Corporation2 questions · 1 reporting period · 0 of 2 challenging
Calendar 2026 Q1
with you rolling it up into instruments now, kind of what should we expect
Show response
Kevin said the reporting change reflects existing structure; investors will gain more visibility into fast-growing Neuro Cranial businesses including IDS, the mild procedure acquisition, and upcoming Sonopet 4 launch.
with Mako 4, maybe how should we be thinking about the installed base growth versus maybe replacing the fleet
Show response
Kevin said Mako 4 utilization is similar to prior generations near-term, but its multifunctionality (hips, knees, revision hip, upcoming shoulder) will drive incremental demand as surgeons won't want to share robots across procedures.
Challenge rate by company
Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.
| Company | Questions | Challenge rate |
|---|---|---|
| SYK Stryker Corporation | 2 | —Rate withheld: fewer than 3 questions |
- SYKStryker Corporation · 2 questions—rate withheld: under 3 questions
Activity by reporting period
Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.
| Calendar period | Questions | Challenge rate | Companies |
|---|---|---|---|
| 2026 Q1 | 2 | 0%none of 2 questions | 1 |
- 2026 Q12 questions · challenge rate 0% (none of 2 questions) · 1 company
Topics
Topics tagged on this analyst’s questions.
- Product Launch2
- Revenue Growth1
- Demand1